SCHEMBL6396759

SCHEMBL6396759

CC(Cc1c(O)cc(O)cc1P(=O)(O)O)c1ccc(O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.46
ESR2 Q92731 5/20 0.46
MIF P14174 1/20 0.35
PDCD1 Q15116 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
SLC28A3 Q9HAS3 1/20 0.34
CYP3A4 P08684 3/20 0.32
ADORA3 P0DMS8 2/20 0.32
CYP2D6 P10635 2/20 0.32
PTGS1 P23219 2/20 0.32
SLC6A2 P23975 2/20 0.32
ADRA1A P35348 2/20 0.32
OPRM1 P35372 2/20 0.32
SLC6A3 Q01959 2/20 0.32
LMNA P02545 1/20 0.32
CYP1A2 P05177 1/20 0.32
PGR P06401 1/20 0.32
CHRM2 P08172 1/20 0.32
AR P10275 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6395045 0.86 ESR1 (0.37) ESR1ESR2MIFPDCD1CD274
SCHEMBL6402288 0.85 HDAC4 (0.38) MIFCYP3A4ADRA1AOPRM1SLC6A3
SCHEMBL6397245 0.83 ESR1 (0.49) ESR1ESR2SLC28A3CYP3A4ADORA3
SCHEMBL20718388 0.83 ESR1 (0.60) ESR1ESR2MIFPDCD1CD274
SCHEMBL6403761 0.83 ESR1 (0.46) ESR1ESR2MIFPDCD1CD274
SCHEMBL6397849 0.80 ESR1 (0.43) ESR1ESR2MIFPDCD1CD274
SCHEMBL6396754 0.80 ESR1 (0.43) ESR1ESR2MIFPDCD1CD274
SCHEMBL6401987 0.79 ESR1 (0.49) ESR1ESR2MIFPDCD1CD274
SCHEMBL6404296 0.77 MEN1 (0.38) ESR1ESR2SLC28A3CYP3A4CYP2D6
SCHEMBL6397011 0.77 ESR1 (0.36) ESR1ESR2MIFPDCD1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ESR1 2885/4885ESR2 2416/4885MIF 1786/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 ESR1 3212/4885ESR2 2699/4885MIF 2109/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ESR1 2885/4885ESR2 2416/4885MIF 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.